Federal Court dismisses motion for a fifth generic to be added to rivaroxaban trial of common issues under PMNOC Regulations

Published date06 December 2019
Subject MatterPatents,Generic Drugs,Pharmaceutical Patents,Canada,Patent Invalidity,Patented Medicines,PMNOC Regulations,Concurrent Litigation
AuthorKatie Lee
Law FirmSmart & Biggar

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT